Elanco Animal Health has included additional information in the canine Atopica licence to give vets more flexible treatment options for canine atopic dermatitis, and to ensure both short and long-term comfort in dogs.

The updated licence now states consideration should be given to the use of other measures and/or treatments to control moderate to severe pruritus when initiating therapy with Atopica.

This pruritus control can be provided by anti-inflammatory doses of prednisolone; the safety and efficacy of this combination has been confirmed in a clinical study1 included on the updated Atopica package leaflet.

The changes to the summary of product characteristics have been made in recognition of the importance of understanding the underlying cause of the itch and, while treating dermatology cases can be a complex process, good clinical practice suggests a tailored, multimodal approach depending on the individual case.

This can be done in three stages:

  • good clinical diagnosis
  • short-term plan – consider all medications to treat secondary infections to get the pet feeling comfortable; for example, parasite control, antibiotics, antipruritics and antifungals, as appropriate
  • long-term plan – treat the underlying cause of the disease as appropriate; for example, a multimodal approach combining Atopica, regular shampooing, diet and essential fatty acids.

To help tackle the root cause of dermatitis in dogs and cats, vets can also use Elanco’s Vet Assist diagnostic tool at http://www.vetassistdermatology.com

Reference 1. Dip R, Carmichael J, Letellier I et al (2013). Concurrent short-term use of prednisolone with cyclosporine A accelerates pruritus reduction and improvement in clinical scoring in dogs with atopic dermatitis, BMC Veterinary Research 9: 173.

View your activity >

Leave a Reply

Be the First to Comment!

Notify of